Question 1

How would you convince a doctor to prescribe your company's medicine over a competitor's?

Accepted Answer

The approach must be ethical and evidence-based: 1) Know the doctor's patient profile — what conditions they commonly treat. 2) Present clinical trial data showing efficacy, safety, and tolerability advantages. 3) Highlight unique benefits: Better bioavailability, fewer side effects, convenient dosage form, better patient compliance. 4) Share real-world evidence and published studies. 5) Provide patient samples for trial. 6) Regular follow-up with more data and feedback collection. Important: Never make unsubstantiated claims. Follow MCI (Medical Council of India) ethics guidelines and UCPMP (Uniform Code of Pharmaceutical Marketing Practices). Build trust over time — long-term relationships matter more than one-time sales.

Question 2

What is the drug approval process in India?

Accepted Answer

The CDSCO (Central Drugs Standard Control Organization) under DCGI oversees drug approvals. Process: 1) Pre-clinical: Lab and animal studies for safety/toxicity. 2) IND Application: Submit to DCGI for permission to conduct human trials. 3) Clinical Trials: Phase 1 (20-100 healthy volunteers — safety), Phase 2 (100-500 patients — efficacy/dosing), Phase 3 (1000-5000 patients — confirmatory). 4) NDA (New Drug Application): Submit all data to DCGI. 5) DTAB (Drug Technical Advisory Board) review. 6) Manufacturing approval from State FDA. 7) Post-marketing surveillance (Phase 4). Timeline: 8-12 years typically. New Drug Rules 2019 allow expedited approvals for breakthrough therapies and drugs approved in developed nations.

Question 3

What is the difference between Phase 1, 2, 3, and 4 clinical trials?

Accepted Answer

Phase 1: Safety and dosage. 20-100 healthy volunteers. Tests pharmacokinetics (how drug is absorbed, distributed, metabolized, excreted) and finds safe dosage range. Duration: Months. Success rate: ~70%. Phase 2: Efficacy and side effects. 100-500 patients with the condition. Determines optimal dosage and monitors adverse effects. Duration: Months to 2 years. Success rate: ~33%. Phase 3: Confirmatory. 1000-5000+ patients, often multi-center randomized controlled trials (RCTs). Compares with standard treatment. Duration: 1-4 years. Success rate: ~25-30%. Phase 4: Post-market surveillance. Ongoing after approval. Monitors long-term effects, rare side effects, usage in broader population. Can lead to label changes or withdrawal. Overall drug development success rate from Phase 1 to approval: ~10-15%.

Question 4

What are the key challenges in Indian healthcare?

Accepted Answer

Major challenges: 1) Access: 70% of India's population lives in rural areas but 80% of doctors are in urban areas. Government spending on healthcare is ~2.1% of GDP (below global average). 2) Affordability: Out-of-pocket expenses are 55%+. 30-40 crore Indians have no health insurance. 3) Quality: Shortage of 6 lakh doctors and 20 lakh nurses. Infrastructure gaps in primary healthcare centers. 4) Digital health: Fragmented records, low telemedicine adoption (improving post-COVID). 5) Public health: Communicable diseases persist alongside rising NCDs (diabetes, heart disease). Solutions being implemented: Ayushman Bharat (world's largest health insurance scheme, 50 crore beneficiaries), ABHA (digital health ID), telemedicine guidelines, PM-JAY expansion, and increased medical college seats.

Healthcare & Pharma Interview Questions & Answers

Pharmaceutical Sales & Marketing

Clinical Research & Healthcare Management

Key Tips for Healthcare Interviews